This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeFirst-line Advanced RCCFirst-line Advanced RCCOverviewEfficacy Measures: OS, PFS, & ORRSafety & Tolerability ProfileDosingTherapy Management StrategiesMOAs – INLYTA and pembrolizumabNCCN Recommendation  PublicationsProfessional ResourcesSecond-line Advanced RCCSecond-line Advanced RCCOverviewEfficacy Measures: PFS, ORR, OS, & Subset AnalysesSafety & Tolerability ProfilePatient Characteristics & Treatment ConsiderationsOral DosingVEGFR Pathway & INLYTA® (axitinib) MOANCCN Recommendation  Patient Support and ResourcesPatient Support and ResourcesPfizer Oncology TogetherEventsMaterials
Prescribing InformationIndicationsPatient Site
Patient Financial Support & ResourcesMaking your patients’ support needs a priority. Together.

At Pfizer Oncology TogetherTM, patient support is at the core of everything we do. We’ve gathered resources and developed tools to help patients and their loved ones throughout INLYTA® (axitinib) treatment. From helping to identify financial assistance options to connecting patients to an array of useful resources, our patients’ needs are our priority.

Visit PfizerOncologyTogether
LoadingPatient Financial Assistance

Pfizer Oncology Together can help patients understand their insurance benefits and connect them with financial assistance resources (if needed), regardless of their insurance coverage.

COMMERCIALLY INSURED

Resources for eligible patients with commercial, private, employer, or state health insurance marketplace coverage:

  • Co-pay assistance: Eligible, commercially insured patients may pay as little as $0 per month for INLYTA. Limits, terms, and conditions apply.* Patients may receive up to $9,450 per product in savings annually. There are no income requirements, forms, or faxing to enroll
 Visit PfizerOncologyTogether LoadingPatients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $9,450 per product in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full Terms and Conditions, please see PfizerOncologyTogether.com/terms. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.MEDICARE/GOVERNMENT INSURED

Help identifying resources for patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans who express a financial need and may be eligible:

  • We can assist patients with searching for financial support from alternate funding resources, which may include financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
  • If support from alternate funding resources or Medicare Extra Help is not available, Pfizer Oncology Together will see if your patient is eligible for the Pfizer Patient Assistance Program,† which can provide prescribed Pfizer Oncology medications for free
UNINSURED

Help identifying resources for patients without any form of health care coverage who may be eligible:

  • We can check patient eligibility for Medicaid and help them understand how to apply
  • Patients who do not qualify for Medicaid may receive free medication through the Pfizer Patient Assistance Program† or at a savings through the Pfizer Savings Program.‡ Patients must be eligible and reapply as needed
The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.The Pfizer Savings Program is not health insurance. For more information, call the toll-free number 1-877-744-5675. There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.NEED INLYTA STARTER SAMPLES?
CONTACT YOUR PFIZER SALES REPRESENTATIVEAccess & Reimbursement Assistance

If patients need access or reimbursement assistance, Pfizer Oncology Together is here to help with:

  • Benefits verification:
    We can help determine a patient’s coverage and out-of-pocket costs
  • Prior authorization (PA) assistance:
    We can coordinate with a patient’s insurer to determine the PA requirements. After your office submits a PA request, we can follow up with the payer until a final outcome is determined
  • Appeals assistance:
    We can review the reasons for a denied claim and provide information on payer requirements. After your office submits an appeal, we can follow up with the payer until a final outcome is determined
  • Specialty pharmacy coordination:
    To help your patients access the medication you’ve prescribed, we can identify specialty pharmacy options. If you prefer, you and your staff can also continue to work directly with specialty pharmacies
  • Dedicated local support:
    Pfizer Oncology Account Specialists can provide detailed information on Pfizer Oncology medications and access resources. In addition, they can help you and your office staff contact a Pfizer Oncology Field Reimbursement Manager (FRM) in your area

Field Reimbursement Managers: To help address specific access issues—in person or over the phone. They can help educate your staff on our access and reimbursement resources and help address challenging or urgent Pfizer Oncology patient cases you have sent to Pfizer Oncology Together.

For live support

Call 1-877-744-5675 (Monday-Friday 8 AM-8 PM ET)

Visit PfizerOncologyTogether
LoadingPfizer Oncology Together Co-Pay Savings ProgramTerms & ConditionsBy using this co-pay card or by mailing in this rebate, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
  • Patients are not eligible to use this card or participate in the rebate program if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patient must have private insurance. Offer is not valid for cash-paying patients.
  • With this card, eligible patients will pay a $0 co-pay per eligible monthly prescription, subject to a maximum amount of $9,450 per product per calendar year. The amount of any benefit is the difference between your co-pay and $0. After the annual maximum of $9,450 per product is reached, you will be responsible for the remaining monthly out-of-pocket costs. This card may not be redeemed more than once per 30 days.
  • This co-pay card and rebate are not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this co-pay card or value received under this rebate from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the co-pay card or receipt of rebate to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card or which the patient receives a rebate, as may be required. You should not use the co-pay card or rebate program if your private insurer or health plan prohibits use of manufacturer coupons, co-pay cards, debit cards or similar savings programs.
  • This co-pay card and rebate are not valid where prohibited by law.
  • The benefit under the co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • This card and rebate cannot be combined with any other savings, free trial, or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs).
  • Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the [coupon/co-pay card] program.
  • This card and rebate cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
  • Card will be accepted only at participating pharmacies.
  • This card and rebate are not health insurance.
  • Offer good only in the U.S. and Puerto Rico.
  • Card is limited to 1 per person during this offering period and is not transferable.
  • No other purchase is necessary.
  • Data related to your redemption of the co-pay card and/or rebate may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke, or amend this offer and rebate program without notice.
  • Offer and rebate program expires 12/31/2024.
  • If your pharmacy does not participate in the co-pay program, you may be able to submit a request for a rebate in connection with this offer:
    • Mail a copy of the patient’s original pharmacy receipt indicating patient name, name of medication purchased, price paid, and date purchased, accompanying your prescription, as proof of purchase, along with a copy of the patient’s Pfizer Oncology Together Co-Pay Savings Card, to: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560. Receipt will not be returned.
    • The patient will receive a maximum of $9,450 per product per calendar year or the amount of the co-pay paid, whichever is less.
    • Rebate will be mailed to patients approximately 6 to 8 weeks after receipt of required documentation or earlier, as required by law.
Patient Support and Resources

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-INL-USA-1507
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
INDICATIONSINLYTA® (axitinib) in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
Important Safety Information

Hypertension including hypertensive crisis has been observed. Ensure that blood pressure is well controlled prior to initiating INLYTA. Monitor for hypertension and treat as needed. Withhold and then dose reduce INLYTA or permanently discontinue based on severity of hypertension.

Arterial and venous thrombotic events have been observed and can be fatal. Use with caution in patients who are at increased risk for, or who have a history of, these events. Permanently discontinue INLYTA if an arterial thromboembolic event occurs during treatment. Monitor for signs and symptoms of VTE and pulmonary embolism. Withhold INLYTA and then resume at same dose or permanently discontinue based on severity of VTE.

Hemorrhagic events, including fatal events, have been reported. INLYTA has not been studied in patients with evidence of untreated brain metastasis or recent active gastrointestinal bleeding and should not be used in those patients. Withhold and then dose reduce INLYTA or discontinue based on severity and persistence of hemorrhage.

Cardiac failure has been observed and can be fatal. Monitor for signs or symptoms of cardiac failure throughout treatment with INLYTA. Management of cardiac failure may require dose reduction, dose interruption or permanent discontinuation of INLYTA.

Gastrointestinal perforation and fistula, including death, have occurred. Use with caution in patients at risk for gastrointestinal perforation or fistula. Monitor for symptoms of gastrointestinal perforation or fistula periodically throughout treatment.

Hypothyroidism requiring thyroid hormone replacement has been reported. Monitor thyroid function before initiation of, and periodically throughout, treatment.

INLYTA has the potential to adversely affect wound healing. Withhold INLYTA for at least 2 days prior to elective surgery. Do not administer INLYTA for at least 2 weeks following major surgery and until adequate wound healing. Resume INLYTA at a reduced dose or discontinue based on severity and persistence of the impaired wound healing. The safety of resuming INLYTA after resolution of wound healing complications has not been established.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed. If signs or symptoms occur, permanently discontinue INLYTA.

Proteinuria has been observed. Monitor for proteinuria before initiation of, and periodically throughout, treatment. For moderate to severe proteinuria, withhold and then dose reduce INLYTA.

Liver enzyme elevation has occurred during treatment with INLYTA as a single agent. INLYTA in combination with pembrolizumab can cause hepatotoxicity with higher than expected frequencies of Grades 3 and 4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation. Monitor ALT, AST, and bilirubin before initiation of, and periodically throughout, treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. Withhold INLYTA and/or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity.

For patients with moderate hepatic impairment, the starting dose of INLYTA should be decreased. INLYTA has not been studied in patients with severe hepatic impairment.

INLYTA can cause fetal harm. Advise patients of the potential risk to the fetus and to use effective contraception. When INLYTA is used in combination with pembrolizumab, refer to the full Prescribing Information of pembrolizumab for pregnancy and contraception information.

Avoid strong CYP3A4/5 inhibitors. If unavoidable, reduce the dose of INLYTA. Grapefruit or grapefruit juice may also increase INLYTA plasma concentrations and should be avoided.

Avoid strong CYP3A4/5 inducers and, if possible, avoid moderate CYP3A4/5 inducers.

Fatal adverse reactions (ARs) occurred in 3.3% of patients receiving INLYTA in combination with pembrolizumab as first-line treatment for advanced RCC. These included 3 cases of cardiac arrest, 2 cases of pulmonary embolism, and 1 case each of cardiac failure, death due to unknown cause, myasthenia gravis, myocarditis, Fournier’s gangrene, plasma cell myeloma, pleural effusion, pneumonitis, and respiratory failure.

The most common (≥20%) ARs (all grades, vs sunitinib) occurring in patients receiving INLYTA in combination with pembrolizumab as first-line treatment for advanced RCC were diarrhea (56% vs 45%), fatigue/asthenia (52% vs 51%), hypertension (48% vs 48%), hepatotoxicity (39% vs 25%), hypothyroidism (35% vs 32%), decreased appetite (30% vs 29%), palmar-plantar erythrodysesthesia (28% vs 40%), nausea (28% vs 32%), stomatitis/mucosal inflammation (27% vs 41%), dysphonia (25% vs 3.3%), rash (25% vs 21%), cough (21% vs 14%), and constipation (21% vs 15%).

The most common (≥20%) Grade 3/4 ARs (vs sunitinib) occurring in patients receiving INLYTA in combination with pembrolizumab as first-line treatment for advanced RCC were hypertension (24% vs 20%) and hepatotoxicity (20% vs 4.9%).

The most common (≥20%) lab abnormalities (all grades, vs sunitinib) occurring in patients receiving INLYTA in combination with pembrolizumab as first-line treatment for advanced RCC included hyperglycemia (62% vs 54%), increased ALT (60% vs 44%), increased AST (57% vs 56%), increased creatinine (43% vs 40%), hyponatremia (35% vs 29%), hyperkalemia (34% vs 22%), hypoalbuminemia (32% vs 34%), hypercalcemia (27% vs 15%), hypophosphatemia (26% vs 49%), increased alkaline phosphatase (26% vs 30%), hypocalcemia (22% vs 29%), increased blood bilirubin (22% vs 21%), prolonged activated partial thromboplastin time (22% vs 14%), lymphopenia (33% vs 46%), anemia (29% vs 65%), and thrombocytopenia (27% vs 78%).

The most common (≥20%) ARs (all grades, vs sorafenib) in patients receiving INLYTA as second-line treatment for advanced RCC were diarrhea (55% vs 53%), hypertension (40% vs 29%), fatigue (39% vs 32%), decreased appetite (34% vs 29%), nausea (32% vs 22%), dysphonia (31% vs 14%), palmar-plantar erythrodysesthesia syndrome (27% vs 51%), weight decreased (25% vs 21%), vomiting (24% vs 17%), asthenia (21% vs 14%), and constipation (20% vs 20%).

The most common (≥10%) Grade 3/4 ARs (vs sorafenib) occurring in patients receiving INLYTA as second-line treatment for advanced RCC were hypertension (16% vs 11%), diarrhea (11% vs 7%), and fatigue (11% vs 5%).

The most common (≥20%) lab abnormalities (all grades, vs sorafenib) occurring in patients receiving INLYTA as second-line treatment for advanced RCC included increased creatinine (55% vs 41%), decreased bicarbonate (44% vs 43%), hypocalcemia (39% vs 59%), decreased hemoglobin (35% vs 52%), decreased lymphocytes (absolute) (33% vs 36%), increased ALP (30% vs 34%), hyperglycemia (28% vs 23%), increased lipase (27% vs 46%), increased amylase (25% vs 33%), increased ALT (22% vs 22%), and increased AST (20% vs 25%).

IndicationS

INLYTA® (axitinib) in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.

Please see full Prescribing Information for INLYTA.